Biotech Acquisition Company and Blade Therapeutics Announce Definitive Merger Agreement

NEW YORK and SOUTH SAN FRANCISCO, Calif.: NEW YORK and SOUTH SAN FRANCISCO, Calif., Nov. 8, 2021 /PRNewswire/ -- Proposed merger to create publicly traded biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases Combined company expected to have post-transaction enterprise value of approximately $352.8 million...

Click to view original post